DDInter758 DDInter899
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Fluoxetine {u} (Compound) resembles {v} (Compound) Orphenadrine
Fluoxetine {u} (Compound) resembles {v} (Compound) Duloxetine
Fluoxetine {u} (Compound) binds {v} (Gene) CYP2D6
Fluoxetine {u} (Compound) upregulates {v} (Gene) ALDOC
Fluoxetine {u} (Compound) palliates {v} (Disease) schizophrenia
Fluoxetine {u} (Compound) downregulates {v} (Gene) RPS4Y1
Fluoxetine {u} (Compound) causes {v} (Side Effect) Cystitis
Fluoxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Fluoxetine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepyramine
Fluoxetine (Compound) resembles Orphenadrine (Compound)
Fluoxetine (Compound) resembles Duloxetine (Compound)
Fluoxetine (Compound) binds CYP2D6 (Gene)
Fluoxetine (Compound) upregulates ALDOC (Gene)
Fluoxetine (Compound) palliates schizophrenia (Disease)
Fluoxetine (Compound) downregulates RPS4Y1 (Gene)
Fluoxetine (Compound) causes Cystitis (Side Effect)
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine